Advanced search    

Search: authors:"Katja Weisel"

5 papers found.
Use AND, OR, NOT, +word, -word, "long phrase", (parentheses) to fine-tune your search.

Erratum zu: Immuntherapie des multiplen Myeloms

Cuny C et al. MRE bei Mensch und Tier: Übertragungswege und Infekti- onsrisiko. Hyg Med. 0 Dr. med. Hans-Martin Wenchel 1 Der Übersichtsartikel von Katja Weisel und Lothar Kanz mit dem Titel ... multiple myeloma“ von Leo Rasche , Niels Weinhold, Gareth J. Morgan , Frits van Rhee und Faith E. Davies [Rasche L et al. Cancer Treat Rev. 2017;55:190-9] 2 Katja Weisel , Lothar Kanz 3 Arzt für Hygiene und

Spotlight on elotuzumab in the treatment of multiple myeloma: the evidence to date

Spotlight on elotuzumab in the treatment of multiple myeloma: the evidence to date Katja Weisel Department of Hematology/Oncology, University Hospital Tuebingen, Tuebingen, Germany Abstract: Despite

Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma

Background Despite novel therapeutic agents, most multiple myeloma (MM) patients eventually relapse. Two large phase III trials have shown significantly improved response rates (RR) of lenalidomide/dexamethasone compared with placebo/dexamethasone in relapsed MM (RMM) patients. These results have led to the approval of lenalidomide for RMM patients and lenalidomide/dexamethasone...

European trial of free light chain removal by extended haemodialysis in cast nephropathy (EuLITE): A randomised control trial

Background Renal failure is a frequent complication of multiple myeloma and when severe is associated with a greatly increased morbidity and mortality. The principal cause of severe renal failure is cast nephropathy, a direct consequence of high concentrations of monoclonal free light chains (FLCs) in patients' sera. FLC removal by extended haemodialysis, using a high cut-off...

DSMM XI study: dose definition for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed myeloma

A clinical trial was initiated to evaluate the recommended dose of cyclophosphamide in combination with bortezomib and dexamethasone as induction treatment before stem cell transplantation for younger patients with newly diagnosed multiple myeloma (MM). Thirty patients were treated with three 21-day cycles of bortezomib 1.3 mg/m2 on days 1, 4, 8, and 11 plus dexamethasone 40 mg...